金斯瑞生物科技(01548.HK)發起的12項研究被採納在第63屆美國血液學會(ASH)年會及博覽會上展示
格隆匯11月4日丨金斯瑞生物科技(01548.HK)公佈,公司非全資附屬公司傳奇生物科技股份有限公司於2021年11月4日宣佈於2021年12月11日至12月14日期間,公司發起的12項研究被採納在第63屆美國血液學會(ASH)年會及博覽會上展示,其中包括兩次口頭報吿和10次海報展示。
報吿的亮點包括展示CARTITUDE系列研究(靶向BCMA的CAR-T療法 — 西達基奧侖賽(Cilta-cel)用於治療復發或難治性多發性骨髓瘤患者)的更新資料,報吿將詳細介紹來自CARTITUDE-1研究1b/2期的長期隨訪資料和新的亞組分析結果,以及將CARTITUDE-1研究中的患者結局與來自於真實世界臨牀實踐LocoMMotion研究中採用標準治療的患者結局經校正後進行間接比較的結果。此外來自在更前線人羣中探索的CARTITUDE-2研究中的Cohort-B的首次資料和Cohort A的長期隨訪資料也將進行展示。
此外,公司還將首次分享新型三特異性單域抗體(VHH) CAR-T(LCAR-AIO)的臨牀前體內資料。LCAR-AIO靶向CD19、CD20和CD22三種抗原,具有用於開發治療複發性B細胞淋巴瘤和既往接受過CD19 CAR-T治療患者的潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.